Background In October 2018, a new heart allocation policy was implemented to risk stratify patients listed for transplant, prioritizing patients supported with temporary mechanical circulatory support (MCS). The policy changes may have had an impact on the management of cardiogenic shock (CS). We sought to determine the changes in use of temporary MCS, durable left ventricular assist device (LVAD) and transplant in patients hospitalized before and after the new policy. Methods A retrospective analysis was conducted using the National Inpatient Sample (NIS) between 2017-2020. Hospitalizations for cardiogenic shock were identified, and stratified based on whether patients were admitted before or after the policy change. Baseline characteristics were compared between cohorts, and the primary outcome of interest was the use of MCS, transplant and LVAD before and after the policy change. Subgroup analyses included patients hospitalized at transplant and non-transplant centers, LVAD recipients as well as those who underwent transplant. Results A total of 643,655 hospitalizations were included, of which 260,340 (40.4%) were before the policy change, and 383,315 (59.6%) were after. In all patients with CS, there was a decrease in the use of LVAD (adjusted OR 0.73, p<0.01) and an increase in cardiac transplant (adjusted OR 1.45, p<0.01). While IABP use declined for the general CS population (adjusted OR 0.81, p<0.01), it increased significantly in cardiac transplant recipients (adjusted OR 2.55; p<0.01). Impella and VA-ECMO also increased in transplant recipients. No uptrend was seen in any other subgroup including LVAD recipients or CS patients managed in transplant centers. Conclusion Our study showed that the allocation policy change had a direct impact on MCS use in the first two years after implementation, but this effect was isolated to patients who underwent transplantation. It will be important to study how policy changes influence the management of other shock populations over time.

Dr Luke Kim has received fellowship grant support from Abbott and Medtronic. Dr. Jim Cheung has received honoraria from Abbott and Medtronic and fellowship grant support from Abbott and Medtronic.

This work was supported by grants from the Michael Wolk Heart Foundation (New York, NY) and the New York Cardiac Center, Inc (New York, NY)). The Michael Wolk Heart Foundation and the New York Cardiac Center, Inc. had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board approval and informed consent were not required for the study as all data collection was derived from a publicly available, de-identified administrative database.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data is available from the National Inpatient Sample (NIS)